In 2017, the CRISPR/Cas9 system effectively abrogates the BCR/ABL1 oncogene and reversed the tumorigenicity in edited CRISPR cells in a CML xenograft animal model [240]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.